Circulating endothelial progenitor cells - PubMed (original) (raw)

Review

Circulating endothelial progenitor cells

B Garmy-Susini et al. Br J Cancer. 2005.

Abstract

Angiogenesis research investigates the formation of new blood vessels in wound healing, tumour growth and embryonic development. Circulating, bone marrow-derived endothelial progenitor cells (EPCs) were first described 8 years ago, yet the exact nature of these endothelial precursor cells remains unclear. The contributions of circulating EPCs to angiogenesis in tumours, ischaemic injury and other diseases as well as their usefulness in the repair of wounded hearts and limbs remain under intense investigation.

PubMed Disclaimer

Figures

Figure 1

Figure 1

Bone marrow-derived endothelial progenitor cells (EPCs) contribute to tumour angiogenesis. Endothelial progenitor cells (purple circles) arise in the bone marrow as CD34+CD133+VEGFR2+ cells. These cells are induced to leave the bone marrow and enter the vasculature by circulating angiogenic factors such as vascular endothelial growth factor (VEGF). Once in the circulation, these cells can arrest at sites of ischaemia or growth factor release (such as VEGF release), such as in the tumour periphery. These cells then can participate in new vessel formation by differentiating into branching blood vessels.

Similar articles

Cited by

References

    1. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM (1997) Isolation of putative progenitor endothelial cells for angiogenesis. Science 275: 964–967 - PubMed
    1. Asahara T, Tomono T, Masuda H, Kalka C, Chen D, Iwaguro H, Inai Y, Silver M, Isner J (1999) VEGF contributes to postnatal neovascularization by mobilizing bone marrow derived endothelial progenitor cells. EMBO J 18: 3964–3972 - PMC - PubMed
    1. Bagley RG, Walter-Yohrling J, Cao X, Weber W, Simons B, Cook BP, Chartrand SD, Wang C, Madden SL, Teicher BA (2003) Endothelial precursor cells as a model of tumor endothelium: characterization and comparison with mature endothelial cells. Cancer Res 63: 5866–5873 - PubMed
    1. Bertolini F, Paul S, Mancuso P, Monestiroli S, Gobbi A, Shaked Y, Kerbel RS (2003) Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res 63: 4342–4346 - PubMed
    1. Chavakis E, Aicher A, Heeschen C, Sasaki K, Kaiser R, El Makhfi N, Urbich C, Peters T, Scharffetter-Kochanek K, Zeiher AM, Chavakis T, Dimmeler S (2005) Role of beta2-integrins for homing and neovascularization capacity of endothelial progenitor cells. J Exp Med 201: 63–72 - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources